Celator Pharmaceuticals

	Management Leadership The senior team at Celator includes industry leaders who have played key roles in the development and commercialization of many pharmaceutical products.
	Scott Jackson, R.Ph., M.B.A. CEO Mr. Jackson was appointed to his current position in April 2008. He joined Celator Pharmaceuticals in October 2007 as Head of Commercial Development. Mr. Jackson has more than 20 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing, and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor (Johnson & Johnson), Eximias Pharmaceuticals and YM BioSciences (acquired Eximias). Mr. Jackson holds a B.S. in Pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from University of Notre Dame.
	Lawrence Mayer, Ph.D., Founder, President & Head of Research Dr. Mayer has played a lead role in the discovery and development of a number of anti-cancer drugs. He held senior management positions at The Canadian Liposome Company and QLT Inc. before joining the BC Cancer Agency, where he directed the Investigational Drug Program. He is currently also adjunct professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia. Dr. Mayer has published more than 120 scientific articles and has been awarded 10 patents related to his research. Dr. Mayer received his B.S. in both Chemistry and Biology (1978), summa cum laude, from Wartburg College and his Ph.D. in Biochemistry (1983) from the University of Minnesota.
	Arthur C. Louie, M.D., Chief Medical Officer Dr. Louie is a board certified oncologist with more than 25 years of experience in pharmaceutical research and development. He was a vice president of medical affairs at Human Genome Sciences Inc. and a vice president of clinical research at Xoma Corporation. He also held leadership roles in clinical development at Pro-Neuron, Inc. Pro-Virus Inc., and Chiron Therapeutics. Dr. Louie was a director of cancer research at Bristol-Myers and consulted for Johnson & Johnson and Genta Incorporated. He was responsible for the successful effort to secure FDA approval for Proleukin IL-2, which is used for treatment of metastatic kidney cancer and for metastatic melanoma. Dr. Louie received a B. A. in Biology with honors from Haverford College, and an M.D. from New York University School of Medicine. He completed oncology fellowships at the National Cancer Institute and at Stanford University.
	John Bennett, Head of Business Development Mr. Bennett most recently was Vice President of Corporate Development for YM BioSciences in Berwyn, PA. Prior to that Mr. Bennett was Senior Vice President Business Development for Aventis Behring responsible for global licensing activities and held various senior positions at Rhone-Poulenc Rorer in business development and finance. Mr. Bennett has more than 20 years experience in the pharmaceutical industry in licensing, mergers and acquisitions and finance, holds a bachelor’s degree in accounting from St. Joseph’s University and is a Certified Public Accountant (CPA).
	Christine Swenson, Ph.D., Head of Preclinical Development Dr. Swenson previously served as Executive Director of Preclinical Development and R&D Site Manager at Elan Pharmaceuticals (previously The Liposome Company). In this capacity, Dr. Swenson advanced non-clinical pharmacology and toxicology programs that ultimately resulted in four successful IND applications in the U.S. and two successful marketing applications for products currently sold in the U.S., Europe and Canada. Dr. Swenson has authored over 50 scientific publications. She earned her Ph.D. from Cornell University Graduate School of Medical Sciences in New York City, and conducted post-doctoral research at Rockefeller University in New York City and at the University of California in San Francisco.
	Donna Cabral-Lilly, Ph.D., Head of Pharmaceutical Development Dr. Cabral-Lilly was formerly Senior Director of Pharmaceutical Development at Control Delivery Systems (CDS), where she was responsible for chemistry, manufacturing and controls programs for several drug delivery products in clinical development. Prior to joining CDS, Dr. Cabral-Lilly was at Elan Pharmaceuticals where she directed the Analytical Research and Development Group. She has authored numerous scientific publications and is credited as inventor on several patents. Dr. Cabral-Lilly was an instructor at Boston University School of Medicine. She earned her Ph.D. from Boston University and was a post-doctoral fellow at Brandeis University.
	David Wood, MBA, CMA, Head of Finance and Corporate Development Mr. Wood has held management positions in both large corporations and early stage companies in Canada and the UK. Most recently he was Managing Director of Cubist Pharmaceuticals (UK) Ltd. Prior to that he was Senior Director, International Operations of Cubist Pharmaceuticals Inc., and Finance Director at TerraGen Discovery, Inc. Mr. Wood received an MBA from the Ivey Business School of the University of Western Ontario, a BSc in Biology, and a CMA accounting designation.